Analyst Price Targets — FBRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 25, 2025 11:34 am | — | Evercore ISI | $65.00 | $19.06 | TheFly | Forte Biosciences initiated with an Outperform at Evercore ISI |
Latest News for FBRX
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.
Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results.
Forte Biosciences (FBRX) offers upside as FB102 demonstrates efficacy in both celiac disease and vitiligo, suggesting platform potential beyond a single indication. FB102's mechanism targets CD122, modulating key immune pathways, with placebo-controlled data showing 21.7% F-VASI benefit in vitiligo and histologic protection in celiac disease. FBRX holds a pro forma cash position of ~$220M post-financing, providing…
Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript
Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b clinical trial results for FB102, an investigational therapy for vitiligo, showing statistically significant improvements in disease severity compared with placebo. Vitiligo is a chronic autoimmune disorder where the immune system destroys melanocytes, the pigment-producing cells responsible for skin color, resulting…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FBRX.
U.S. House Trading
No House trades found for FBRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.